NEW YORK — Alzpath said on Monday that it has licensed a proprietary Alzheimer's disease biomarker to Siemens Healthineers for use in an assay for the brain disorder.

The company intends to use the funding to advance its AI-powered microscopy system for infectious disease analysis.

The collaboration combines Guardant's diagnostics with Trial Library's AI-powered matching and patient navigation platform.

With the approval, the company's automated clinical mass spec system, the Cobas I 601 analyzer, features an in vitro diagnostic menu of 39 tests.

NEW YORK – With its $275 million buy of Foresight Diagnostics announced last week, Natera plans to expand into the hematological oncology market and boost sensitivity of its flagship Signatera solid ...

CBO's recent score tallied temporary PAMA delay as a cost rather than a savings, potentially making future delays less likely ...

The German startup is developing ultrasensitive lateral flow diagnostic tests that incorporate DNA origami signal amplification.

The digital immunoassay platform is designed to detect and quantify proteins at the single-molecule level in blood, serum, or plasma. The platform includes the Simoa HD-X Immunoassay Analyzer, which ...